Q1 Earnings Estimate for GENB Issued By HC Wainwright

Generate Biomedicines Inc (NASDAQ:GENB) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Generate Biomedicines in a research note issued to investors on Monday, April 13th. HC Wainwright analyst M. Kapoor expects that the company will earn ($0.44) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. HC Wainwright also issued estimates for Generate Biomedicines’ Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.01) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.49) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.01) EPS.

A number of other brokerages have also recently issued reports on GENB. Piper Sandler assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating for the company. The Goldman Sachs Group started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target for the company. Morgan Stanley assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $20.00 price target on the stock. Finally, Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.20.

Generate Biomedicines Stock Performance

Shares of NASDAQ:GENB opened at $12.50 on Wednesday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $15.32.

Generate Biomedicines News Summary

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: HC Wainwright initiated coverage on Generate Biomedicines with a “Buy” rating and a $16 price target, signaling analyst conviction and potential upside from current levels. Coverage Initiated at HC Wainwright
• Neutral Sentiment: The analyst provided detailed quarterly and annual EPS models for 2026–2027 that give investors a clear baseline for expectations (examples: Q1’26 -$0.44, Q2’26 -$0.48, Q3’26 -$0.54, Q4’26 -$0.56; FY2026 -$2.01; Q1’27 -$0.53, Q2’27 -$0.49, Q3’27 -$0.49, Q4’27 -$0.50; FY2027 -$2.01). These estimates help set benchmarks for future results and valuation assumptions.
• Negative Sentiment: Forecasts show sustained quarterly losses and an annual loss of about $2.01 in both FY2026 and FY2027, underlining that Generate remains pre‑profit and likely reliant on external funding or partnerships — a continuation of cash burn that can weigh on the stock until clinical or commercial milestones are achieved.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.